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Abstract The overexpression or amplification of the
human epidermal growth factor receptor 2 gene (HER2/
neu) is associated with high risk of brain metastasis (BM).
The identification of patients at highest immediate risk of
BM could optimize screening and facilitate interventional
trials. We performed gene expression analysis using com-
plementary deoxyribonucleic acid-mediated annealing,
selection, extension and ligation and real-time quantitative
reverse transcription PCR (qRT-PCR) in primary tumor
samples from two independent cohorts of advanced HER2
positive breast cancer patients. Additionally, we analyzed
predictive relevance of clinicopathological factors in this
series. Study group included discovery Cohort A (84
patients) and validation Cohort B (75 patients). The only
independent variables associated with the development of
early BM in both cohorts were the visceral location of first
distant relapse [Cohort A: hazard ratio (HR) 7.4, 95 % CI
2.4–22.3; p \ 0.001; Cohort B: HR 6.1, 95 % CI 1.5–25.6;
p = 0.01] and the lack of trastuzumab administration in the
metastatic setting (Cohort A: HR 5.0, 95 % CI 1.4–10.0;
p = 0.009; Cohort B: HR 10.0, 95 % CI 2.0–100.0;
p = 0.008). A profile including 13 genes was associated
with early (B36 months) symptomatic BM in the discovery
cohort. This was refined by qRT-PCR to a 3-gene classifier
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(RAD51, HDGF, TPR) highly predictive of early BM (HR
5.3, 95 % CI 1.6–16.7; p = 0.005; multivariate analysis).
However, predictive value of the classifier was not con-
firmed in the independent validation Cohort B. The pre-
sence of visceral metastases and the lack of trastuzumab
administration in the metastatic setting apparently increase
the likelihood of early BM in advanced HER2-positive
breast cancer.
Keywords Breast cancer  Brain metastasis  HER2 
RAD51  HDGF  TPR
Introduction
The overexpression or amplification of the human epider-
mal growth factor receptor 2 gene (HER2/neu) is associ-
ated with high risk of brain metastasis (BM).
Approximately 30–50 % of advanced HER2-positive
breast cancer patients will develop BM, with an annual risk
of around 10 % [1–5]. It has been speculated that
improvements in systemic therapy resulting in greater
numbers and more durable systemic responses may permit
more time for BM relapse. Trastuzumab, a monoclonal
antibody that targets the extracellular domain of HER2, is
used in combination with chemotherapy to improve the
survival of patients with HER2-positive tumors [6–10].
However, owing to its high molecular weight, penetration
of trastuzumab into the central nervous system is extremely
low, 1/420th of serum levels [11], and this compound is
ineffective in treating established BM.
The development of BM predictors in advanced breast
cancer patients might have practical clinical implications.
First, the use of imaging to detect occult BM in unselected
patients is controversial, whereas this strategy may be rea-
sonable in patients at highest immediate risk. Second, reli-
able predictive factors may improve selection of patients in
clinical trials assessing the efficacy of putative BM preven-
tion strategies, such as prophylactic cranial irradiation or the
use of brain-permeable compounds. Finally, these studies
may prompt new therapeutic strategies.
In the present study we analyzed the risk of early BM
according to gene expression, and clinical and pathological
variables in two well annotated cohorts of advanced HER2-
positive breast cancer patients.
Materials and methods
Patients
This study was approved by the Institutional Review Board
of the coordinating centers (Medical University of Gdan´sk,
Poland and Indiana University, USA). Two patient cohorts
were derived from a consecutive series of 315 advanced
HER2-positive breast cancer patients treated in nine
oncology centers in Poland and Serbia between 1993 and
2010 (consort diagram; Fig. 1). Discovery Cohort A
(n = 167) and an independent validation Cohort B
(n = 148) were collected between 2006–2008 and
2008–2010, respectively. According to standard clinical
practice, no screening for occult BMs was used, therefore
almost all BM were symptomatic. BM were defined as
metastatic lesions involving the brain parenchyma, with or
without accompanying leptomeningeal disease. Demo-
graphic and clinicopathologic data, as well as treatments
and clinical follow-up were extracted from institutional
databases or original patient files. Treatments were rule
based (Table 1). Dominant metastatic sites were assigned
into three categories: soft tissue, bones and viscera. Dom-
inant metastatic site was classified by the category asso-
ciated with the worst prognosis in the following order of
increasing gravidity: soft tissue, bones, viscera [12].
Pathology review
The starting material from each patient was a formalin-
fixed, paraffin embedded specimen of primary breast can-
cer. A pre-cut section of each tumor, stained with hema-
toxylin and eosin, was reviewed by two pathologists (SB
and WB) to confirm the presence of sufficient invasive
breast cancer component (1 cm2 invasive tissue, C30 %
tumor cells). In Cohorts A and B, 90/167 and 75/148
tumors, respectively, had sufficient material for molecular
analysis. Expression of ER and PR was determined using
immunohistochemistry (IHC), with 10 % of nuclear stain-
ing considered as a positive result. HER2 protein expres-
sion was determined using semiquantitative IHC
(HercepTest, Dako A/S, Glostrup, Denmark) or HER-2/
neuTest 4B5 (Ventana Medical Systems, Inc.). Only sam-
ples showing strong expression (scored 3?), defined as
uniform, and intense membrane staining of at least 10 % of
invasive tumor cells, were considered positive. The sam-
ples showing intermediate expression (scored 2?) were
subjected to additional analysis of HER2 gene copy num-
ber using fluorescence in situ hybridization (FISH). Gene
amplification by FISH was defined as a FISH ratio (HER2/
centromeric probe for chromosome 17 ratio) of greater than
2.0. FISH-positive patients were considered HER2-
positive.
RNA extraction
Tumor cells were processed using macrodissection to
enrich their population for analysis. Sections were depa-
raffinized with CitriSolv clearing agent (Fisher Scientific
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Company, Fair Lawn, NJ) and scraped off from the slide
into a microcentrifuge tube. Total RNA was extracted from
three 10 lm thick whole tissue sections from each sample
using the Roche high pure RNA paraffin kit according to
manufacturer’s instructions (Roche Applied Science,
Indianapolis, IN). Purified total RNA samples were stored
frozen at -80 C until needed for quality control (QC)
analysis and subsequent gene expression profiling and
quantitative reverse transcription PCR (qRT-PCR). The
concentration of RNA was measured using Nanodrop
ND-1000 spectrophotometer (ThermoScientific, Wilming-
ton, DE). RNA (200 ng) was reverse-transcribed to com-
plementary deoxyribonucleic acid (cDNA) using iScript
cDNA synthesis kit (Bio-Rad Laboratories, Inc., Hercules,
CA). To prequalify RNA samples, SYBR Green-based
qRT-PCR (Applied Biosystems, Foster City, CA) was
performed for RPL13A ribosomal protein gene according
to Illumina’s instructions (San Diego, CA).
DASL analysis
Cohort A samples were analyzed by annealing, selection,
extension and ligation (DASL) assay using Cancer Panel
v1 to provide expression data on 502 known cancer genes.
DASL was performed with the Sentrix universal array
(Illumina, San Diego, California) as per the manufacturer’s
instructions [13] and blinded to patient outcome. Shortly, a
20-ll RT reaction containing a reaction mix (MMC; Illu-
mina, San Diego, CA), biotinylated random hexamers and
oligo-d(T)18, and total RNA, was incubated at room tem-
perature for 10 min and then at 42 C for 1 h. Pooled assay
oligos were annealed to their sequence-specific targets on
the cDNA under a controlled hybridization program. The
cDNA was immobilized on paramagnetic beads and
washed to remove any excess or mis-hybridized oligos.
Hybridized oligos were then extended and ligated to gen-
erate amplifiable templates, using Illumina-supplied
reagents and conditions (BeadStation User’s Manual, Illu-
mina). A PCR reaction was performed with Cy3 labeled
universal PCR primers. Single-stranded PCR products were
prepared by denaturation, and were then hybridized to
Sentrix arrays under a temperature gradient program. The
arrays were imaged using a BeadArray Reader scanner
(Illumina). The DASL assay was performed three times
independently, and samples were hybridized to three dif-
ferent array matrices. The 502-gene assay was available in
Discovery Cohort A
(material collected 2006-2008) 
First step (DASL analysis; year 2008) 
Total patients collected
(N=167) 
↓
Eligible
(N=110) 
↓
Excluded due to poor material quality   
(N=20) 
↓
Tumor content allowing  
molecular analysis
(N=90; 87 analyzed)
↓
Second step (qPCR analysis; year 2012, 
with longer follow-up) 
(N=87) 
↓
Excluded due to insufficient amount of 
mRNA (N=3) or lost to follow-up (N=3)  
↓
Analyzed 
(N=84; one non analyzable) 
Validation Cohort B
(material collected 2008-2010) 
Total patients collected 
(N=148)  
↓
Eligible
(N=81) 
↓
Excluded due to equivocal HER2 status  
or poor material quality
(N=6)
↓
Tumor content  allowing  
molecular analysis
(N=75) 
↓
Analyzed
(N=75) 
Fig. 1 Consort diagram
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Table 1 Patient characteristics
Variables Discovery Cohort A
N = 84
Validation Cohort B
N = 75
p
Age at diagnosis
Mean 50 52 0.07
Range 29–75 28–71
Age at brain metastases
Mean 47.6 51.5 0.03
Range 30–64 33–69
N % N %
Brain metastases
No 36 43 34 45 0.75
Yes 48 57 41 55
Menopausal status
Premenopausal 43 51 28 37 0.07
Postmenopausal 40 48 47 63
Histology
Ductal 70 83 58 77 0.02
Lobular 6 7 5 7
Other 1 1 3 4
Uncertain 0 0 7 9
Ductal and lobular 6 7 2 3
Grades
2 35 46 34 49 0.69
3 41 54 35 51
ER (IHC)
Negative 52 63 43 57 0.49
Positive 31 37 32 43
PR (IHC)
Negative 59 71 54 72 0.89
Positive 24 29 21 28
Breast cancer surgery
No 16 19 15 20 0.91
Yes 67 81 60 80
Radiotherapy
No 38 46 25 34 0.12
Adjuvant 27 32 28 37
Definitive 0 0 1 1
Palliative 13 17 10 13
Combination thereof 4 5 11 15
Chemotherapy induction
No 49 59 55 73 0.06
Yes 34 41 20 27
Chemotherapy
No 2 2 1 1 0.22
Adjuvant 11 13 19 25
For metastatic disease 15 18 9 12
Combination thereof 56 67 46 61
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a 96-well format; this enabled analysis of all the samples in
a single batch. Built-in internal controls and replicate
samples were used to analyze stability of the assay. The r2
values for the duplicate samples were greater than 0.95.
Generation of the 13-gene signature
Cohort A samples were divided into an internal training set
and an internal testing set. Predictive analysis of microarray
analysis (http://www-stat.stanford.edu/*tibs/PAM/) was
performed to identify multigene profiles predictive for BM.
The best gene-expression signature was selected based on a
built-in 10-fold cross-validation analysis in PAM. Then the
gene-signature was output as a single variable from the
PAM. Its association with the BM free survival (BMFS) was
analyzed in the internal testing set with a Cox regression
analysis, in which clinical and demographic variable effects
were justified. This analysis was performed with the R
function, coxph. The gene signature construction from the
internal training set used the optimal variable selection
strategy in PAM, and p value was not considered. Then, the
correlation between the gene signature and BMFS was
assessed by the Cox regression model, and the p value\0.05
was considered as statistically significant.
Table 1 continued
N % N %
Trastuzumab therapy
No 13 16 12 16 0.72
Adjuvant 2 2 2 3
For metastatic disease 68 81 58 77
Combination thereof 1 1 3 4
Anti-HER2 tyrosine kinase inhibitors
No 72 86 51 68 0.02
Adjuvant 0 0 2 3
For metastatic disease 12 14 22 29
Endocrine therapy
No 44 52 41 55 0.85
Adjuvant/neoadjuvant 21 25 21 28
For metastatic disease 8 10 6 8
Combination thereof 11 13 7 9
Type of first progression
Local 2 2 10 13 0.02
Regional 3 4 3 4
Distant 77 92 56 75
Local/regional and/or distant 2 2 6 8
Dominant site of metastatic disease
Soft tissue 4 5 16 22 0.001
Bone 3 4 7 10
Visceral 77 91 50 68
Location of first extracranial visceral relapse
Lung 23 28 25 35 0.19
Liver 34 41 26 36
Other 16 19 15 21
Lung and liver 8 10 2 3
Lung and other 0 0 3 4
Liver and other 2 2 1 1
Brain as first relapse
No 77 93 67 89 0.45
Yes 6 7 8 11
Significant values marked in bold
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
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Real-time qRT-PCR analysis
Owing to the abandoning of the 502-gene DASL assay by
the manufacturer, and to increase the potential utility of the
profile, we switched to a qRT-PCR assay. Apart from its
clinical applicability, this method allows precise quantifi-
cation of transcriptional abundance of identified genes.
TaqMan reactions were performed in triplicates using
custom array microfluidic cards preloaded with TaqMan
gene expression assays containing 16 genes (13 discrimi-
nant genes and 3 reference genes) on an ABI Prism
7900HT fast real-time platform according to the manu-
facturer’s instructions. The primer sequences are listed in
Table 2. Transferrin receptor (TFRC), beta cytoskeletal
actin (ACTB) and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) were used as endogenous reference controls
for normalization. Delta threshold cycle (DCt) values for
each of the 13 genes of interest were normalized using the
three endogenous reference controls according to the
method of Applied Biosystem’s DataAssistTM Software.
All procedures were performed blinded to patient out-
comes. After normalization, 2DCt values were subject to
Table 2 List of genes constituting a 13-gene profile and TaqMan probes used in qRT-PCR analysis
Gene symbols Gene names Human assay ID Amplicon length (bp)
CDK4 Cyclin dependent kinase 4 Hs00175935_m1 65
CCNC Cyclin C Hs00193177_m1 78
PTK2 Focal adhesion kinase (protein tyrosine kinase 2) Hs00178587_m1 68
MYC v-myc avian myelocytomatosis viral oncogene homolog Hs99999003_m1 65
BARD1 BRCA1 associated RING domain 1 Hs00184427_m1 73
RAD51 RAD51 homolog Hs00153418_m1 58
FANCG Fanconi anemia group G Hs00184947_m1 116
PCNA Proliferating cell nuclear antigen Hs00696862_m1 95
PRCC Papillary renal cell carcinoma-translocation associated Hs00410541_m1 77
TPR Translocated promoter region Hs00162918_m1 82
CTTN Cortactin Hs00193322_m1 81
DSP Desmoplakin Hs00189422_m1 74
HDGF Hepatoma-derived growth factor Hs00610314_m1 110
ACTB Actin, beta, cytoplasmic Hs00357333_g1 77
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Hs99999905_m1 122
TFRC Transferrin receptor Hs99999911_m1 105
Selected controls: ACTB, GAPDH, TFRC
Table 3 Factors associated with early brain metastases (B36 months)
Variables Univariate analysis Multivariate analysis*
HR 95 % CI p HR 95 % CI p
Discovery Cohort A
ER negative versus positive 3.3 1.1–10.0 0.03 2.8 0.9–9.1 0.07
Visceral site of first distant relapse 4.5 1.9–10.7 0.001 7.4 2.4–22.3 <0.001
13-Gene expression high versus low 5.6 1.9–16.5 0.002 8.5 2.6–28.0 <0.001
3-Gene classifier high versus low 3.7 1.3–11.1 0.01 5.3 1.6–16.7 0.005
Trastuzumab therapy for metastatic disease no versus yes 3.3 1.1–10.0 0.02 5.0 1.4–10.0 0.009
Validation Cohort B
ER negative versus positive 2.5 0.9–10.0 0.09 5.0 1.1–10.0 0.04
Visceral site of first distant relapse 5.9 1.8–19.7 0.003 6.1 1.5–25.6 0.01
3-Gene classifier high versus low 1.2 0.3–20.0 0.8 NC
Grade high versus low 3.3 1.1–14.3 0.03 3.8 0.9–16.7 0.07
Trastuzumab therapy for metastatic disease no versus yes 2.5 1.0–10.0 0.06 10.0 2.0–100.0 0.008
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the leave-one-out cross-validated linear discriminant ana-
lysis (LDA), and coefficients for the individual genes were
chosen. The coefficients for the individual genes and
individual gene expression data for each patient were col-
lated to develop an individual score, which was used for
statistical analysis in both cohorts.
Statistical analysis
All statistical analyses were performed using STATA
software version 11. Statistical significance was defined as
p \ 0.05. Gene expression data were normalized at the
median level. Hierarchical clustering and singular value
decomposition methods were applied to detect the outliers
for QC purposes. The false discovery rate (FDR), an esti-
mate of the proportion of errors committed by falsely
rejecting null hypotheses was calculated for each gene.
Categorical variables in both cohorts (including correlation
of the developed 3-gene classifier with clinicopathologic
variables) were compared using Pearson’s Chi squared test
(v2). Survival curves were plotted using Kaplan–Meier
method starting from date of primary breast cancer diag-
nosis to date of death or last follow-up. The BMFS was a
primary endpoint and was defined from date of primary
breast cancer diagnosis to date of BM diagnosis, death of
any cause, or date of last follow-up. Univariate survival
analysis and time to diagnosis of BM within 36 months in
Cohorts A and B were performed with log-rank test, Wil-
coxon test and Cox proportional hazard regression and
controlled for the competing risk of death [14]. Multivar-
iate analysis used a stepwise forward selection of univari-
ate model with p B 0.20.
Fig. 2 Cohort A. Distribution
of the 13 gene transcript
expression obtained from the
RNA isolation process in DASL
and qRT-PCR. a DASL (data
was normalized using quantile
normalization), b qRT-PCR
normalized using the
endogenous reference controls
(ACTB, GAPDH, TFRC). The
graph shows apparent inter-
panel discordance of BARD1,
CCNC and HDGF expression,
and minor inter-panel
discordance of FANCG and
PCNA expression
J Neurooncol (2015) 122:205–216 211
123
Results
Characteristics and outcomes of study cohorts
Discovery Cohort A
Of the 84 primary tumors subjected to analysis in the
Cohort A, 83 were analyzable (Fig. 1). The patient mean
age was 48 years (range 30–64), with the patients roughly
divided between pre- and post-menopausal status
(Table 1). Eighty three percent of the tumors were invasive
ductal cancers, 63 % were ER-negative and 71 % PR-
negative. Ninety two percent of patients had dominant
visceral metastatic disease; 98 % of patients received
chemotherapy and 48 % endocrine therapy in adjuvant
and/or metastatic setting. More than 40 % of patients
received induction chemotherapy and 87 % of patients
were administered trastuzumab in adjuvant or metastatic
Table 4 Relationship between
the 3-gene classifier and other
variables
Significant values marked in
bold
ER estrogen receptor, PR
progesterone receptor, HER2
human epidermal growth factor
receptor 2
Variables 3-Gene classifier
Discovery Cohort A (N = 83) Validation Cohort B (N = 75)
Low
(N = 34; 41 %)
High
(N = 49; 59 %)
Low
(N = 63; 84 %)
High
(N = 12; 16 %)
N % N % p N % N % p
Menopausal status
Premenopausal 20 60 23 47 24 38 4 33 0.75
Postmenopausal 13 40 26 53 0.22 39 62 8 67
Primary tumor grades
2 20 67 15 33 28 49 6 50 0.95
3 10 33 30 67 0.05 29 51 6 50
ER
Negative 16 47 36 75 35 56 8 67 0.47
Positive 18 53 12 25 0.01 28 44 4 33
PR
Negative 23 68 36 75 45 71 9 75 0.80
Positive 11 32 12 25 0.46 18 29 3 25
Induction chemotherapy
No 21 62 28 58 50 79 5 42 0.007
Yes 13 38 20 42 0.75 13 21 7 58
Endocrine therapy
No 12 36 31 63 33 52 8 67 0.36
Yes 22 65 18 37 0.01 30 48 4 33
Trastuzumab for metastatic disease
No 3 9 13 26 15 24 2 17 0.59
Yes 31 91 36 73 0.04 48 76 10 83
Visceral location of first relapse
No 31 94 34 69 44 73 9 75 0.90
Yes 2 6 15 31 0.01 16 27 3 25
First site of visceral metastasis
Lung 11 33 12 25 22 37 3 25 0.05
Liver 16 48 18 37 22 37 4 33
Other 2 6 13 27 13 22 2 17
Lung and liver 4 12 4 8 0 0 2 17
Lung and other 0 0 0 0 2 3 1 8
Liver and other 0 0 2 4 0.19 1 2 0 0
Brain metastases
No 11 32 25 51 28 44 6 50
Yes 23 67 24 49 0.09 35 55 6 50 0.72
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setting, usually in combination with chemotherapy. In
14 % of patients lapatinib was administered at trastuzumab
relapse. Follow-up from breast cancer diagnosis varied
from 1 to 185 months. Within this period, 48 patients
developed symptomatic BM. The median time from initial
breast cancer to BM diagnosis was 36 months (range
2–141 months). In 7 % of patients brain was the first site of
distant relapse, with or without accompanying extracranial
relapse. After BM, HER2 directed treatments included
trastuzumab (33 % of patients), lapatinib (15 %) and either
used sequentially (4 %). Seventy seven percent of patients
received cranial radiotherapy. The median overall survival
(OS) from the initial diagnosis of breast cancer was
44 months (range 0.9–185 months).
Validation Cohort B
The Cohort B, including 75 analyzable cases, was similar
to Cohort A in terms of age, ER and PR expression, and
tumor grade (Table 1). However, Cohort B included sig-
nificantly more non-ductal cancers, patients were older at
BM development and had different patterns of relapse
(fewer distant relapses as the first failure, more first
relapses in the visceral organs and fewer visceral dominant
metastatic sites). Furthermore, more patients in this cohort
received lapatinib following failure of trastuzumab. The
median time to diagnosis of BM in this cohort was longer
(40 months; range 0.33–125 months, compared to
36 months in Cohort A), and so was the median OS
(50 months; range 11–186 months, compared to 44 months
in Cohort A). In Cohort B 41 patients developed BM,
including 16 that occurred within 36 months from
diagnosis.
Determinants of BMFS and OS
Performed in Cohort A binary comparison for presence or
absence of BM among 502 analyzed genes did not show
any differential gene expression (25 having p \ 0.05, a
FDR of 1.0). However, a gene expression analysis in 22
and 21 patients who developed BM within 36 months (the
median time to diagnosis of BM) versus thereafter,
respectively, identified differential expression of 48 genes
with p \ 0.01 and FDR = 0.1. Predictive analysis of
microarray analysis identified a 13-gene profile [cyclin
dependent kinase 4 (CDK4), cyclin C (CCNC), focal
adhesion kinase (protein tyrosine kinase 2, PTK2), v-myc
avian myelocytomatosis viral oncogene homolog (MYC),
BRCA1 associated RING domain 1 (BARD1), RAD51
homolog (RAD51), Fanconi anemia group G (FANCG),
proliferating cell nuclear antigen (PCNA), papillary renal
cell carcinoma-translocation associated (PRCC), translo-
cated promoter region (TPR), cortactin (CTTN),
desmoplakin (DSP), hepatoma-derived growth factor
(HDGF)] at effectively distinguished patients with early
versus late BM [hazard ratio (HR) 5.6, 95 % CI 1.9–16.5;
p = 0.002 in the univariate analysis; HR 8.5, 95 % CI
2.6–28.0; p \ 0.001 in the multivariate analysis; Table 3].
The microarray data have been deposited in NCBI’s gene
expression omnibus (http://www.ncbi.nlm.nih.gov/geo;
GSE38057).
In order to increase the potential clinical applicability of
this signature, a qRT-PCR based analysis of the 13 genes
(and 3 references) was performed and showed promising
preliminary results [15, 16]. The TaqMan gene expression
assay IDs for each gene was chosen to meet FFPE sample
requirements for custom TLDA based on Applied Bio-
systems guidelines. As expected, DASL and qRT-PCR had
inherent differences related to the platform (Fig. 2). As the
next step, a leave-one-out LDA was performed using an
updated database that had a longer follow-up (5 years)
data. A predictive model that included only 3 of the ori-
ginal 13 genes: HDGF, RAD51 and TPR, with corre-
sponding LDA coefficients of 1.06, 0.35 and -1.08,
respectively, was developed. The 3-gene classifier was
highly predictive of early BM both in univariate (HR 3.7,
95 % CI 1.3–11.1; p = 0.01) and multivariate analysis
(HR 5.3, 95 % CI 1.6–16.7; p = 0.005; Table 3). High
3-gene classifier was associated with tumor grade 3, ER-
negativity and less frequent use of endocrine treatment and
trastuzumab in the adjuvant and/or metastatic setting
(Table 4). Additionally, patients with high 3-gene classifier
were more likely to develop the first relapse in the visceral
organs.
In an independent Cohort B the mean qRT-PCR
expression of 13 genes was different compared to Cohort
A, and only 16 % of patients (compared to 59 % in Cohort
A) were assigned to the high-risk group (Table 4).
Accordingly, the 3-gene classifier was not predictive of
early BM (HR 1.2, 95 % CI 0.3–20.0; p = 0.8; Table 3). In
this cohort the high 3-gene classifier was associated with
less frequent use of induction chemotherapy and more lung
and liver metastases (Table 4).
In the multivariate analysis, in both cohorts the visceral
location of first distant relapse (Cohort A: HR 7.4, 95 % CI
2.4–22.3; p \ 0.001; Cohort B: HR 6.1, 95 % CI 1.5–25.6;
p = 0.01) and the lack of trastuzumab administration in the
metastatic setting (HR 5.0, 95 % CI 1.4–10.0; p = 0.009
and HR 10.0, 95 % CI 2.0–100.0; p = 0.008, respectively)
correlated with early BM (Table 3). ER-negativity had a
strong trend in Cohort A (HR 2.8, 95 % CI 0.9–9.1;
p = 0.07) and was significant in Cohort B (HR 5.0, 95 %
CI 1.1–10.0; p = 0.04).
In both cohorts the independent variables associated
with shorter OS included higher tumor grade (HR 1.9,
95 % CI 1.1–3.3; p = 0.02; HR 1.9, 95 % CI 1.4–3.2;
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p = 0.03), ER negativity (HR 2.0, 95 % CI 1.1–3.3;
p = 0.03; HR 2.5, 95 % CI 1.4–5.0; p \ 0.01) and the lack
of primary tumor surgery (HR 5.0, 95 % CI 2.0–10.0;
p \ 0.01; HR 3.3, 95 % CI 1.7–10.0; p \ 0.01).
Discussion
The aim of this study was to identify molecular predictors
of the BM development in advanced HER2-positive breast
cancer patients. This subset of breast cancer patients carry
particularly high risk of BM. Additionally, some studies
suggested increased risk of BM associated with the use of
trastuzumab [17].
The current study employed a high throughput DASL
technology based on the expression of 502 cancer related
genes in addition to analysis of the clinicopathologic
variables. This targeted gene analysis did not demonstrate
any differential gene expression in patients who did and did
not develop BM. This may likely be due to the limited
number of genes analyzed, but it is also possible that BM in
advanced HER2-positive breast cancer patients is a bio-
logically determined, stochastic and inevitable event. Fur-
ther analysis of the DASL led to identification of a 13-gene
profile that was apparently predictive for development of
early BM [15]. For precise quantification of transcriptional
abundance of identified genes, we employed qRT-PCR
technology, which identified a 3-gene classifier (RAD51,
HDGF, TPR), also seemingly predictive for early BM.
However, the significance of this classifier was not con-
firmed in the independent cohort.
The retrospective design of this study made it difficult to
control for major clinicopathologic differences between
Cohorts A and B. In consequence, patients in Cohort B had
fewer ductal carcinomas and, even more importantly, less
frequently received neoadjuvant chemotherapy. Gene
expression alterations of breast cancer were recently
demonstrated to be drug-specific, and drug-induced tumor
gene signatures may be more informative than unchal-
lenged signatures in predicting treatment outcomes [18,
19]. The study by Bos et al. [20] showed that BM gene set
tested in various breast cancer cohorts was less BM pre-
dictive in patients whom received postoperative systemic
therapy compared to those whom did not. This confirms the
hypothesis that systemic therapies, apart from their pre-
ventive effect, may also alter the pattern of relapse in breast
cancer. In this study, patients in Cohort B, compared to
Cohort A, had also infrequent first relapse at distant sites
and significantly fewer visceral metastases. Furthermore,
much more patients in this cohort received lapatinib at
trastuzumab relapse (32 %, compared to 14 % in Cohort
A). The pivotal study by Geyer et al. [21] showed that the
addition of lapatinib to capecitabine after progression on
trastuzumab resulted in decreased BM occurrence, and
preclinical studies show that lapatinib prevents BMs for-
mation by 53 % in a HER2-transfected model system [22].
The abovementioned differences between both cohorts led
to better general prognosis in Cohort B compared to Cohort
A, expressed by longer OS and time to diagnosis of BM.
Finally, the imbalanced proportion of patients with high
gene classifier in both cohorts (59 % in Cohort A vs. 16 %
in Cohort B) might have largely impacted study results.
Although the gene signature could not be validated, it
identified a number of genes that could be important in the
development of BM. The most important of which is
RAD51, a gene involved in homologous recombination in
DNA double strand breaks repair [20]. RAD51 expression
has been linked to response to neoadjuvant therapy [23–
25]. We have previously reported that high cytoplasmic
expression of RAD51 in breast cancer is associated with
significantly increased risk of BM, particularly in combi-
nation with high Ki-67 index and ER-negativity [26].
Further, in other study demonstrated that BARD1 and
RAD51 are frequently overexpressed in BMs from breast
cancer and may constitute a mechanism to overcome
reactive oxygen species-mediated genotoxic stress in the
metastatic brain [27]. Taken together, this data suggest that
RAD51 targeting might be important in HER2-positive
breast cancer. High nuclear expression of HDGF, another
gene constituting our 3-gene signature, was earlier found to
associate with high tumor grade, Ki-67[20 %, lymph node
involvement and poor prognosis in breast cancer patients
[28, 29]. Chen et al. [29] demonstrated that nuclear HDGF
over-expression stimulates epithelial–mesenchymal transi-
tion of breast cancer cells by down-regulation of E-cad-
herin and up-regulation of vimentin. The third gene of our
signature—TPR, a translocated promoter region nuclear
basket protein, is poorly characterized but has a normal
function in nuclear pore function and is the target of
oncogenic fusions [30].
In the current study, the clinical factors associated with
early development of BM were visceral location of first
relapse and, at a borderline level, ER-negativity, the two
hallmarks of tumor aggressiveness. This is partly consistent
with our earlier study in advanced HER2-positive breast
cancer patients, showing the association between the risk of
BM and shorter time to first extracranial progression [5].
The association between ER-negativity and the occurrence
of BM in HER2-positive breast cancer patients was earlier
reported by other authors [2, 4, 31, 32]. Indeed, the clinical
behavior including tumor kinetics and sites of recurrence in
ER-positive/HER2 positive (HER2-positive luminal B)
breast cancer is different compared to that in non-luminal
HER2 enriched subtype [31–34]. We also showed that
trastuzumab administration in the metastatic setting may
reduce the risk of early BM. This is in line with two other
214 J Neurooncol (2015) 122:205–216
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studies, that noticed shorter time to development of BM in
HER2-positive patients who never received trastuzumab
[35, 36].
Conclusions
We demonstrated that the presence of visceral metastases and
the lack of trastuzumab administration in the metastatic set-
ting apparently increase the likelihood of early BM in
advanced HER2-positive breast cancer, and the 3-gene clas-
sifier does not improve their predictive value. Our study also
illustrates the difficulties in developing clinically useful pre-
dictive markers in the retrospective setting [37]. In our case
these included problems associated with archival tissue col-
lection, heterogeneity of patient populations and inconsistent
therapeutic approaches over the study period. Further studies,
including larger and more homogeneous groups, are necessary
to identify biomarkers, which may help in designing BM
preventive trials and prompt new treatment strategies.
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